ANGN News and Press, Angion Biomedica Corp.

2023-06-01 08:17:12 ET Angion Biomedia ( NASDAQ: ANGN ) has announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion’s common stock will begin trading on a split-adjusted basis when the market opens...

NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...

NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...

NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...

NEW YORK, NY / ACCESSWIRE / March 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:IND...

Clinical-stage biotechnology company, Elicio Therapeutics to merge wit h a wholly-owned subsidiary of Angion Biomedica ( NASDAQ: ANGN ) in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancin...

Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology Lead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, current...

Angion Biomedica ( NASDAQ: ANGN ) said Thursday that it got a letter from Nasdaq notifying that company is not in compliance with the minimum bid price requirement as per certain listing rules. The letter is only a notification of deficiency and not a notice of delisting...

UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it rece...

Angion Biomedica press release ( NASDAQ: ANGN ): Q2 GAAP EPS of -$0.30. Revenue of $0.7M misses by $0.08M . For further details see: Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M